This Phase 2 randomized, controlled, open-label clinical trial evaluated the efficacy of oral methylene blue (MB) in hospitalized patients with severe COVID-19. Eighty patients were randomized to receive either MB plus standard of care (SOC) or SOC alone. The MB group showed significant improvements in oxygen saturation (SpO₂) and respiratory
